Paludatus Pharmaceuticals LLC was founded in Austin, Texas in 2022 by industry veterans Dr. John W. Kozarich and Dr. Lin Zhi, and Professor, Dr. Zucai Suo, based on state-of-the-art proprietary prodrug technologies and knowhow and an IND-approved drug candidate, CAPE-127.
We intend to develop small molecule prodrugs for unique opportunities for unmet medical needs in major pharmaceutical markets.
CAPE-127 is our lead candidate. It is an oral prodrug that treats liver cancer and metastasis from solid tumors such as colorectal cancer (MCRC) and breast cancer.
Our technology platforms LTP TECHNOLOGY™ and BEPro Technology enable us to develop first- or best-in-class novel prodrugs delivering clinically validated nucleotides to target tissues with higher tissue specificity and efficiency, leading to improved safety and efficacy.
The paludamentum was a cloak fastened at one shoulder, worn by Roman military commanders. When the general goes forth to war and they have changed into the paludamentum and have sounded the signals, he is said to set forth paludatus. The name "Paludatus" symbolizes that we have engaged in the battle against diseases and we are armed with drugs that are "cloaked" as prodrugs to effectively and decisively engage our opponent.
The paludamentum was dyed with a rare and very expensive color called tyrian purple. We have chosen this color as our company's primary color to further symbolize our name and our mission.
To develop novel prodrugs for unmet medical needs to save and sustain lives.